文献速递心力衰竭与心肌病

强化心衰管理对比标准管理对医疗费用的影响:多中心随机对照试验

Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.
PubMed 文献 · Eur Heart J · 2017-01-01

这项多中心随机对照试验纳入787例慢性心衰出院患者,随机分为标准管理组(SM,n=391)和基于个体化风险分层的强化管理组(INT-HF-MP,n=396)。12个月随访显示,INT-HF-MP组的总医疗费用与SM组无差异(中位数1579 vs 1450澳元/患者/月),全因死亡率和再住院天数亦无显著差异。

要点

  • 强化心衰管理项目未降低12个月总医疗费用。
  • 两组全因死亡率无显著差异(17.7% vs 18.4%)。
  • 两组再住院天数无显著差异(18.6 vs 16.6天)。

核心结论

  • 在12个月随访期间,基于个体化风险分层的强化心衰管理项目(INT-HF-MP)与标准管理相比,未降低医疗费用,也未改善健康结局。

研究设计与样本

  • 多中心随机对照试验,纳入787例慢性心衰出院患者(完整分析集),随机分为标准管理组(SM,n=391)和强化管理组(INT-HF-MP,n=396)。

主要发现

  • INT-HF-MP组的总医疗费用中位数为1579澳元/患者/月(IQR 644-3717),SM组为1450澳元/患者/月(IQR 564-3615),两组无差异。
  • INT-HF-MP组全因死亡率为17.7%,SM组为18.4%(P=0.848),无显著差异。
  • INT-HF-MP组再住院天数为18.6±26.5天,SM组为16.6±24.8天(P=0.199),无显著差异。
  • 应用INT-HF-MP的中位成本为152澳元/患者/月,显著高于SM组的121澳元/患者/月(P<0.001)。

关键数值与推荐

  • INT-HF-MP根据GARDIAN-HF风险分层(绿、黄、红)给予面对面家访和结构化电话支持联合管理;仅9%低风险患者接受与SM组相同水平的管理。

临床怎么用

  • 对于慢性心衰出院患者,基于个体化风险分层的强化管理项目在12个月内未显示降低医疗费用或改善健康结局。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To determine if an intensified form of heart failure management programme (INT-HF-MP) based on individual profiling is superior to standard management (SM) in reducing health care costs during 12-month follow-up (primary endpoint). METHODS AND RESULTS: A multicentre randomized trial involving 787 patients (full analysis set) discharged from four tertiary hospitals with chronic HF who were randomized to SM (n = 391) or INT-HF-MP (n = 396). Mean age was 74 ± 12 years, 65% had HF with a reduced ejection fraction (31.4 ± 8.9%) and 14% were remote-dwelling. Study groups were well matched. According to Green, Amber, Red Delineation of rIsk And Need in HF (GARDIAN-HF) profiling, regardless of location, patients in the INT-HF-MP received a combination of face-to-face (home visits) and structured telephone support (STS); only 9% (`low risk') were designated to receive the same level of management as the SM group. The median cost in 2017 Australian dollars (A$1 equivalent to ∼EUR €0.7) of applying INT-HF-MP was significantly greater than SM ($152 vs. $121 per patient per month; P < 0.001), However, at 12 months, there was no difference in total health care costs for the INT-HF-MP vs. SM group (median $1579, IQR $644 to $3717 vs. $1450, IQR $564 to $3615 per patient per month, respectively). This reflected minimal differences in all-cause mortality (17.7% vs. 18.4%; P = 0.848) and recurrent hospital stay (18.6 ± 26.5 vs. 16.6 ± 24.8 days; P = 0.199) between the INT-HF-MP and SM groups, respectively. CONCLUSION: During 12-months follow-up, an INT-HF-MP did not reduce healthcare costs or improve health outcomes relative to SM.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Scuffham PA, Ball J, Horowitz JD, et al. Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial. Eur Heart J. 2017. PMID: 28531281. doi:10.1093/eurheartj/ehx259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。